ABUSE-DETERRENT FORMULATION & PRODUCT TESTING FOR PHARMACEUTICAL & MEDICAL DEVICE INDUSTRIES

The development of a new drug or therapy is a high-risk venture. Any setbacks with the FDA can be costly and time-consuming to correct. This is especially true for compounds with high abuse potential.  NMS Labs has the experience and knowledge of current FDA Guidance on Abuse-Deterrence to design and conduct the highest quality Risk Evaluation and Mitigation Strategy (REMS) study and provide a report that is FDA-ready - from a trusted and unbiased third party source.  

Why Abuse Deterrence Matters

  • Per CDC data, opioids responsible for 33,000+ deaths in the U.S. in 2015
  • ADF play a crucial role in combating prescription drug abuse epidemic
  • ADF studies are critical for NDA filings & may help obtain FDA fast track 
  • Commonly studied drug formulations include:
    • Opioid-based products
    • Cannabinoid-based substances
    • Amphetamine & stimulant-based products
    • Extended & immediate release formulations
    • Transdermal devices
    • Over-the-counter (OTC) products
    • Pseudoephedrine to Methamphetamine conversion

drug diversion web image.jpg


Replicating Diversion Techniques

We perform a wide range of "kitchen-type" experiments to challenge drug delivery devices to their limits and compare to currently available formulations.  We then take the outcomes and quantitate by LC-MS/MS to measure, evaluate drug diversion report web image2.jpgand report detailed and scientifically backed conclusions.

The NMS Advantage

  • 12+ years of experience and success in Abuse Deterrent Formulation Testing
  • Highly-trained team, including former DEA experts
  • Proven, consultative approach based on consistent results and clear communication -> effective partnerships


Learn More

More information can be found here.

Call us or email NMS Labs today to talk about your specific needs.



« Return to Testing & Services by Category


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9